Abstract:Cardiovascular diseases (CVDs) represent a significant global health burden, demanding innovative therapeutic approaches. In recent years, mRNA therapeutics have emerged as a promising strategy to combat CVDs effectively. Unlike conventional small-molecule drugs, mRNA therapeutics enable the direct modulation of cellular functions by delivering specific mRNA molecules to target cells. This approach offers unprecedented advantages, including the ability to harness endogenous cellular machinery for protein synthesis, thus allowing precise control over gene expression without insertion into the genome. This review summarizes the current status of the potential of cell-specific mRNA therapeutics in the context of cardiovascular diseases. First, it outlines the challenges associated with traditional CVD treatments and emphasizes the need for targeted therapies. Subsequently, it elucidates the underlying principles of mRNA therapeutics and the development of advanced delivery systems to ensure cell-specificity and enhanced efficacy. Notably, innovative delivery methods such as lipid nanoparticles and exosomes have shown promise in improving the targeted delivery of mRNA to cardiac cells, activated fibroblasts, and other relevant cell types. Furthermore, the review highlights the diverse applications of cell-specific mRNA therapeutics in addressing various aspects of cardiovascular diseases, including atherosclerosis, myocardial infarction, heart failure, and arrhythmias. By modulating key regulatory genes involved in cardiomyocyte proliferation, inflammation, angiogenesis, tissue repair, and cell survival, mRNA therapeutics hold the potential to intervene at multiple stages of CVD pathogenesis. Despite its immense potential, this abstract acknowledges the challenges in translating cell-specific mRNA therapeutics from preclinical studies to clinical applications like off-target effects and delivery. In conclusion, cell-specific mRNA therapeutics have emerged as a revolutionary gene therapy approach for CVD, offering targeted interventions with the potential to significantly improve patient outcomes.

Cell therapy for cardiovascular disease: a comparison of methods of delivery

Comments about Possible Use of Human Embryonic Stem Cell-Derived Cardiomyocytes to Direct Autologous Adult Stem Cells into the Cardiomyogenic Lineage

The Recent Advances in Cell Delivery Approaches, Biochemical and Engineering Procedures of Cell Therapy Applied to Coronary Heart Disease

Biomaterials‐based Cell Therapy for Myocardial Tissue Regeneration

Cardiac-derived stem cell-based therapy for heart failure: progress and clinical applications.

Concise Review: Optimized Strategies for Stem Cell-based Therapy in Myocardial Repair: Clinical Translatability and Potential Limitation.

Stem cell therapy for cardiac regeneration: past, present, and future

Stem Cell Therapy For Ischemic Heart Diseases

Stem Cell Therapy: A New Therapeutic Option for Cardiovascular Diseases

Current Optimized Strategies for Stem Cell-Derived Extracellular Vesicle/exosomes in Cardiac Repair.

Cardiac Cell Therapy: Insights into the Mechanisms of Tissue Repair

Retrograde Coronary Venous Infusion as a Delivery Strategy in Regenerative Cardiac Therapy: an Overview of Preclinical and Clinical Data

Mesenchymal stem cell delivery strategies to promote cardiac regeneration following ischemic injury

Non-viral reprogramming and induced pluripotent stem cells for cardiovascular therapy

Cell-Specific mRNA Therapeutics for Cardiovascular Diseases and Regeneration

Choice of cell-delivery route for successful cell transplantation therapy for the heart

Stem cell and exosome therapies for regenerating damaged myocardium in heart failure

Current Research on Cell Transplantation for Cardiovascular Diseases

Targeted cell delivery of mesenchymal stem cell therapy for cardiovascular disease applications: a review of preclinical advancements

Mini Review: Recent Advances in the Cell-Based Therapies for Cardiac Regeneration.

Translational cardiac stem cell therapy: advancing from first-generation to next-generation cell types